World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
40273
World Ranking
10331
National Ranking
566

Christoph Sarrazin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christoph Sarrazin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 843 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christoph Sarrazin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christoph Sarrazin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christoph Sarrazin is affiliated with Goethe University Frankfurt in Germany and has a significant research output in the field of medicine, with a particular emphasis on hepatology. Their body of work spans a range of related subfields including epidemiology, infectious diseases, rheumatology, and cardiology and cardiovascular medicine.

Their research predominantly focuses on liver-related conditions and viral hepatitis. This is reflected in their main topics of study which include:

  • Hepatitis C virus research
  • Liver disease diagnosis and treatment
  • Hepatitis B virus studies
  • Liver disease and transplantation
  • HIV/AIDS drug development and treatment
  • Systemic lupus erythematosus research
  • Hepatitis viruses studies and epidemiology

Christoph Sarrazin has contributed extensively to scientific literature with several recent papers published in renowned journals. Notable publications include:

  • "Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)", 2021, Journal of Hepatology
  • "JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection", 2020, Gastroenterology
  • "Treatment failure with DAA therapy: Importance of resistance", 2021, Journal of Hepatology
  • "Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries", 2023, Journal of Hepatology
  • "Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy", 2020, Journal of Hepatology

Their collaborations include frequent co-authors such as Stefan Zeuzem, Julia Dietz, Christiana Graf, Thomas Berg, and Peter Buggisch, indicating a consistent engagement with experts in related fields.

Christoph Sarrazin's research has been published most often in these venues:

  • Journal of Hepatology
  • Zeitschrift für Gastroenterologie
  • JHEP Reports
  • Journal of Viral Hepatitis
  • Liver International

Their work on liver-related diseases, viral hepatitis, and antiviral therapies contribute to ongoing efforts in medical research into diagnosis, treatment, and epidemiology of these conditions.

Best Publications

  • EASL Recommendations on Treatment of Hepatitis C

    Jean-Michel Pawlotsky;Alessio Aghemo;Geoffrey Dusheiko;Xavier Forns

  • Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

    Sarah Blach;Stefan Zeuzem;Michael Manns;Ibrahim Altraif

  • Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis

    Mireen Friedrich-Rust;Mei-Fang Ong;Swantje Martens;Christoph Sarrazin

  • Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

    Devin Razavi-Shearer;Ivane Gamkrelidze;Mindie H Nguyen;Ding-Shinn Chen

  • Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography

    Mireen Friedrich-Rust;Katrin Wunder;Susanne Kriener;Fariba Sotoudeh

  • Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

    Christoph Sarrazin;Tara L. Kieffer;Doug Bartels;Brian Hanzelka

  • Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

    Thomas Berg;Michael von Wagner;Samer Nasser;Christoph Sarrazin

  • Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

    Christoph Sarrazin;Stefan Zeuzem

  • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3

    Stefan Zeuzem;Rolf Hultcrantz;Marc Bourliere;Tobias Goeser

  • A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis

    Stephan Buch;Felix Stickel;Eric Trépo;Michael Way

  • The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.

    Christoph Sarrazin

  • Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis.

    Mireen Friedrich-Rust;Mei-Fang Ong;Eva Herrmann;Volker Dries

  • Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

    Tara L. Kieffer;Christoph Sarrazin;Janice S. Miller;Martin W. Welker

  • Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

    Tobias J. Weismüller;Tobias J. Weismüller;Palak J. Trivedi;Annika Bergquist;Mohamad Imam;Mohamad Imam

  • Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure

    Andreas Kribben;Guido Gerken;Sebastian Haag;Stefan Herget–Rosenthal

  • Treatment predictors of a sustained virologic response in hepatitis B and C

    Annika Kau;Johannes Vermehren;Christoph Sarrazin

  • Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues†

    Florian van Bömmel;Robert A. de Man;Heiner Wedemeyer;Katja Deterding

  • SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders

    Christoph Sarrazin;Christoph Sarrazin;Regine Rouzier;Frank Wagner;Nicole Forestier;Nicole Forestier

  • Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.

    Florian van Bömmel;Bernhard Zöllner;Christoph Sarrazin;Ulrich Spengler

  • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients

    Stefan Zeuzem;Rolf Hultcrantz;Marc Bourliere;Tobias Goeser

Frequent Co-Authors

Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Eva Herrmann
Eva Herrmann Goethe University Frankfurt
Heiner Wedemeyer
Heiner Wedemeyer Hannover Medical School
Michael P. Manns
Michael P. Manns Hannover Medical School
Stefan Mauss
Stefan Mauss Université Paris Cité
Markus Cornberg
Markus Cornberg Hannover Medical School
Ulrich Spengler
Ulrich Spengler University of Bonn
Maria Buti
Maria Buti Instituto de Salud Carlos III
Christophe Moreno
Christophe Moreno Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and complementary career pathways is important for those interested in the healthcare field. Online degrees now make advanced education more accessible and affordable, allowing students to pursue specialized healthcare roles alongside or instead of traditional medical degrees.

If you're looking for leadership opportunities within healthcare, consider researching the most affordable online mha programs. These degrees prepare graduates for administrative and managerial roles in hospitals, clinics, and public health organizations without the need for on-campus attendance.

Nurses wanting to reach the highest levels of practice may be interested in the least expensive dnp programs available online. Similarly, those focused on pharmacy careers can look into accredited online pharmacy schools to obtain their PharmD remotely.

For students interested in merging technology and healthcare, studying at online schools for health information management could lead to careers in data management, informatics, or IT for healthcare organizations.

Online healthcare degrees offer flexible options to advance your career and open diverse pathways beyond the traditional route to becoming a physician.

Best Scientists Citing Christoph Sarrazin

Trending Scientists

Recently Published Articles